Aktie A2NB5X PHARMAGREEN BIOTECH INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Pharmagreen Biotech Inc.

Aktien

A2NB5X

US71716C1099

PHBI

Markt geschlossen - OTC Markets
Andere Börsenplätze
 21:50:17 07.05.2024 		% 5 Tage % 1. Jan.
0.0009 USD +20.00% Intraday Chart für Pharmagreen Biotech Inc. +12.50% +50.00%
21.02. Pharmagreen Biotech Inc. meldet Ergebnis für das erste Quartal bis zum 31. Dezember 2023 CI
09.01. Pharmagreen Biotech Inc. meldet Ergebnis für das am 30. September 2023 endende Geschäftsjahr CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Pharmagreen Biotech Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023
Pharmagreen Biotech Inc. Reports Earnings Results for the Full Year Ended September 30, 2023
Sub-Penny Momentum Watchlist (TMGI, BEGI, PHBI, ABQQ)
Pharmagreen Biotech Inc. cancelled the transaction announced on November 2, 2022
PHBI – Pharmagreen Starts Sales of MaxGenomicTM Supplement on Amazon.com and Develops Its Next Pre-Workout Formulation
Pharmagreen Starts Sales of MaxGenomicTM Supplement on Amazon.Com and Develops Its Next Pre-Workout Formulation
Pharmagreen Biotech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023
Pharmagreen Biotech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023
PHARMAGREEN BIOTECH INC. : Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits (form 8-K)
Pharmagreen Biotech Inc. Reports Earnings Results for the First Quarter Ended December 31, 2022
PHARMAGREEN BIOTECH INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
Pharmagreen Biotech, Inc. Launches Online Sales for Its MaxGenomic(TM) Supplement Product
PHBI Pharmgreen Launches Online Sales for Its MaxGenomic™ Supplement Product
PHARMAGREEN BIOTECH INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)
Pharmagreen Biotech Inc. Reports Earnings Results for the Full Year Ended September 30, 2022
Pharmagreen Biotech Inc. Auditor Raises 'Going Concern' Doubt
PHARMAGREEN BIOTECH INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Other Events, Financial Statements and Exhibits (form 8-K)
Pharmagreen Appoints Tyrell Crosby, a Professional Athlete, as Its Honorary Sports Ambassador
Pharmagreen Biotech Inc. announced that it expects to receive $0.05 million in funding from JanBella Group, LLC
PHBI Pharmagreen Biotech Appoints Ethan Styles as Vice President of Product Research and Development
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2NB5X Aktie
  4. Nachrichten Pharmagreen Biotech Inc.
  5. Andere Sprachen